(CDNA) CareDx - Overview

Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 1.119m USD | Total Return: 22.2% in 12m

Transplant Diagnostics, Genetic Testing, Management Software
Total Rating 54
Safety 38
Buy Signal 0.08
Diagnostics & Research
Industry Rotation: +1.9
Market Cap: 1.12B
Avg Turnover: 13.3M
Risk 3d forecast
Volatility75.0%
VaR 5th Pctl11.5%
VaR vs Median-8.83%
Reward TTM
Sharpe Ratio0.66
Rel. Str. IBD77.2
Rel. Str. Peer Group49.3
Character TTM
Beta0.638
Beta Downside0.143
Hurst Exponent0.299
Drawdowns 3y
Max DD65.96%
CAGR/Max DD0.60
CAGR/Mean DD1.25
EPS (Earnings per Share) EPS (Earnings per Share) of CDNA over the last years for every Quarter: "2021-03": 0.14, "2021-06": 0.11, "2021-09": 0.07, "2021-12": -0.03, "2022-03": -0.13, "2022-06": -0.13, "2022-09": -0.06, "2022-12": -0.07, "2023-03": -0.11, "2023-06": -0.18, "2023-09": -0.18, "2023-12": -0.17, "2024-03": -0.03, "2024-06": 0.25, "2024-09": 0.14, "2024-12": 0.18, "2025-03": 0.1, "2025-06": 0.1, "2025-09": 0.28, "2025-12": 0.12, "2026-03": 0.34,
Last SUE: 1.66
Qual. Beats: 3
Revenue Revenue of CDNA over the last years for every Quarter: 2021-03: 67.4, 2021-06: 74.188, 2021-09: 75.589, 2021-12: 79.22, 2022-03: 79.416, 2022-06: 80.634, 2022-09: 79.359, 2022-12: 82.384, 2023-03: 77.262, 2023-06: 70.301, 2023-09: 67.192, 2023-12: 65.569, 2024-03: 72.049, 2024-06: 92.274, 2024-09: 82.883, 2024-12: 86.579, 2025-03: 84.685, 2025-06: 86.679, 2025-09: 100.055, 2025-12: 108.386, 2026-03: 117.7,
Rev. CAGR: 12.93%
Rev. Trend: 88.9%
Last SUE: 1.55
Qual. Beats: 1

Warnings

Altman Z'' -10.89 < 1.0 - financial distress zone

Choppy

Tailwinds

Confidence

Description: CDNA CareDx

CareDx, Inc. (CDNA) is a precision medicine company specializing in diagnostic testing and software solutions for transplant patients. Its core business model centers on donor-derived cell-free DNA (dd-cfDNA) and gene expression profiling tests designed to monitor organ health and detect rejection in kidney, heart, and lung transplant recipients. The company also provides human leukocyte antigen (HLA) typing products and transplant patient management software to clinical laboratories and transplant centers.

The transplant diagnostics sector is characterized by high barriers to entry due to stringent regulatory requirements and the necessity for extensive clinical validation data. CareDx operates in a specialized niche where recurring revenue is often driven by the lifelong monitoring needs of transplant survivors. The company maintains a strategic partnership with Illumina, Inc. to facilitate the development and distribution of next-generation sequencing (NGS) technologies.

Investors can further evaluate these market dynamics and company fundamentals by reviewing the data on ValueRay. CareDx remains headquartered in Brisbane, California, and continues to expand its portfolio into cell therapy monitoring and digital health solutions for the transplant ecosystem.

Headlines to Watch Out For
  • Medicare reimbursement policy shifts for donor-derived cell-free DNA testing
  • Volume growth in kidney and heart transplant surveillance services
  • Operational margin expansion through reduced legal expenses and cost restructuring
  • Competitive dynamics within the high-resolution HLA typing and genomics market
  • Integration of digital health software and pharmacy services into transplant workflows
Piotroski VR-10 (Strict) 6.5
Net Income: -8.19m TTM > 0 and > 6% of Revenue
FCF/TA: 0.16 > 0.02 and ΔFCF/TA 11.74 > 1.0
NWC/Revenue: 46.08% < 20% (prev 76.48%; Δ -30.40% < -1%)
CFO/TA 0.18 > 3% & CFO 72.9m > Net Income -8.19m
Net Debt (-144.8m) to EBITDA (10.1m): -14.38 < 3
Current Ratio: 3.40 > 1.5 & < 3
Outstanding Shares: last quarter (53.1m) vs 12m ago -3.86% < -2%
Gross Margin: 68.56% > 18% (prev 0.68%; Δ 6.79k% > 0.5%)
Asset Turnover: 91.67% > 50% (prev 70.75%; Δ 20.92% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -10.89
A: 0.46 (Total Current Assets 269.4m - Total Current Liabilities 79.2m) / Total Assets 411.1m
B: -1.78 (Retained Earnings -732.5m / Total Assets 411.1m)
C: -0.02 (EBIT TTM -10.7m / Avg Total Assets 450.4m)
D: -7.58 (Book Value of Equity -738.8m / Total Liabilities 97.5m)
Altman-Z'' = -10.89 = D
Beneish M -3.32
DSRI: 0.52 (Receivables 44.6m/71.5m, Revenue 412.8m/346.4m)
GMI: 0.99 (GM 68.56% / 67.62%)
AQI: 1.30 (AQ_t 0.21 / AQ_t-1 0.16)
SGI: 1.19 (Revenue 412.8m / 346.4m)
TATA: -0.20 (NI -8.19m - CFO 72.9m) / TA 411.1m)
Beneish M = -3.32 (Cap -4..+1) = AA
What is the price of CDNA shares?

As of May 27, 2026, the stock is trading at USD 21.54 with a total of 476,914 shares traded.
Over the past week, the price has changed by +4.61%, over one month by -1.42%, over three months by +14.45% and over the past year by +22.18%.

Is CDNA a buy, sell or hold?

CareDx has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy CDNA.

  • StrongBuy: 4
  • Buy: 1
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CDNA price?
Analysts Target Price 25.8 19.8%
CareDx (CDNA) - Fundamental Data Overview as of 27 May 2026
Market Cap USD = 1.12b (1.12b USD * 1.0 USD.USD)
P/E Forward = 94.3396
P/S = 2.7117
P/B = 3.5639
P/EG = -0.12
Revenue TTM = 412.8m USD
EBIT TTM = -10.7m USD
EBITDA TTM = 10.1m USD
 Long Term Debt = unknown (none)
 Short Term Debt = unknown (none)
 Debt = 42.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 24.5m
Net Debt = -144.8m USD (calculated: Debt 42.3m - CCE 187.2m)
Enterprise Value = 974.6m USD (1.12b + Debt 42.3m - CCE 187.2m)
 Interest Coverage Ratio = unknown (Ebit TTM -10.7m / Interest Expense TTM 0.0)
 EV/FCF = 14.95x (Enterprise Value 974.6m / FCF TTM 65.2m)
FCF Yield = 6.69% (FCF TTM 65.2m / Enterprise Value 974.6m)
FCF Margin = 15.79% (FCF TTM 65.2m / Revenue TTM 412.8m)
Net Margin = -1.98% (Net Income TTM -8.19m / Revenue TTM 412.8m)
Gross Margin = 68.56% ((Revenue TTM 412.8m - Cost of Revenue TTM 129.8m) / Revenue TTM)
Gross Margin QoQ = 71.43% (prev 66.62%)
Tobins Q-Ratio = 2.37 (Enterprise Value 974.6m / Total Assets 411.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 42.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -8.47m (EBIT -10.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.40 (Total Current Assets 269.4m / Total Current Liabilities 79.2m)
Debt / Equity = 0.14 (Debt 42.3m / totalStockholderEquity, last quarter 313.5m)
Debt / EBITDA = -14.38 (Net Debt -144.8m / EBITDA 10.1m)
Debt / FCF = -2.22 (Net Debt -144.8m / FCF TTM 65.2m)
Total Stockholder Equity = 313.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.82% (Net Income -8.19m / Total Assets 411.1m)
RoE = -0.78% (Net Income TTM -8.19m / Total Stockholder Equity 1.05b)
RoCE = -3.23% (EBIT -10.7m / Capital Employed (Total Assets 411.1m - Current Liab 79.2m))
 RoIC = -4.16% (negative operating profit) (NOPAT -8.47m / Invested Capital 203.6m)
 WACC = 7.93% (E(1.12b)/V(1.16b) * Re(8.23%) + D(42.3m)/V(1.16b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 11.11 | Cagr: 0.34%
[DCF] Terminal Value 77.97% ; FCFF base≈47.2m ; Y1≈54.1m ; Y5≈79.6m
[DCF] Fair Price = 25.99 (EV 1.20b - Net Debt -144.8m = Equity 1.34b / Shares 51.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.66 | # QB: 3
Revenue Correlation: 88.85 | Revenue CAGR: 12.93% | SUE: 1.55 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.23 | Chg30d=+34.88% | Revisions=+20% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.19 | Chg30d=+1.08% | Revisions=N/A | Analysts=5
EPS current Year (2026-12-31): EPS=0.93 | Chg30d=+34.20% | Revisions=N/A | GrowthEPS=+61.0% | GrowthRev=+20.0%
EPS next Year (2027-12-31): EPS=1.13 | Chg30d=+3.85% | Revisions=N/A | GrowthEPS=+21.4% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +20%